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Abstract 
Background: The unrestricted use of linezolid has been linked to the emergence of linezolid-resistant Staphylococcus 
epidermidis (LRSE). We report the effects of combined antibiotic stewardship and infection control measures on the 
spread of LRSE in an intensive care unit (ICU).
Methods: Microbiological data were reviewed to identify all LRSE detected in clinical samples at an ICU in southwest 
Germany. Quantitative data on the use of antibiotics with Gram-positive coverage were obtained in defined daily 
doses (DDD) per 100 patient-days (PD). In addition to infection control measures, an antibiotic stewardship interven-
tion was started in May 2019, focusing on linezolid restriction and promoting vancomycin, wherever needed. We 
compared data from the pre-intervention period (May 2018–April 2019) to the post-intervention period (May 2019–
April 2020). Whole-genome sequencing (WGS) was performed to determine the genetic relatedness of LRSE isolates.
Results: In the pre-intervention period, LRSE were isolated from 31 patients (17 in blood cultures). The average con-
sumption of linezolid and daptomycin decreased from 7.5 DDD/100 PD and 12.3 DDD/100 PD per month in the pre-
intervention period to 2.5 DDD/100 PD and 5.7 DDD/100 PD per month in the post-intervention period (p = 0.0022 
and 0.0205), respectively. Conversely, vancomycin consumption increased from 0.2 DDD/100 PD per month to 4.7 
DDD/100 PD per month (p < 0.0001). In the post-intervention period, LRSE were detected in 6 patients (4 in blood 
cultures) (p = 0.0065). WGS revealed the predominance of one single clone.
Conclusions: Complementing infection control measures by targeted antibiotic stewardship interventions was ben-
eficial in containing the spread of LRSE in an ICU.
Keywords: Antimicrobial stewardship, Infection control, Antimicrobial resistance, Linezolid, Staphylococci, Whole-
genome sequencing
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Background
Staphylococcus epidermidis belongs to the group of 
coagulase-negative staphylococci and is a major constitu-
ent of the human skin flora [1]. Its detection in micro-
biological samples is often interpreted as contamination 
and/or colonization. In nosocomial infections, however, 
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S. epidermidis can play an important role, especially in 
immunocompromised patients or those with indwell-
ing catheters or other foreign bodies [2, 3]. Treatment 
of clinically relevant S. epidermidis infections frequently 
requires the use of glycopeptides, oxazolidinones or lipo-
peptide antibiotics, as resistance to beta-lactams is wide-
spread among S. epidermidis strains [4].
The oxazolidinone antibiotic linezolid acts as an inhibi-
tor of bacterial protein synthesis, and was approved for 
the treatment of infections caused by Gram-positive 
organisms in 2000 [5]. While vancomycin has remained 
the drug of choice for infections caused by methicillin-
resistant Staphylococcus aureus (MRSA), linezolid has 
gained importance as an alternative, especially in MRSA 
pneumonia, but also in infections caused by vancomycin-
resistant enterococci (VRE) [6]. There is no associated 
nephrotoxicity related to the use of linezolid, making it a 
favoured antibiotic especially in critically ill patients with 
impaired renal function. In contrast, the nephrotoxicity 
encountered with the use of vancomycin requires strin-
gent therapeutic drug monitoring, to ensure efficient 
drug levels while at the same time avoiding toxicities.
While the first reports on linezolid resistance were 
attributed to spontaneous point mutations [7], which 
mainly affect the 23S rRNA binding site or the 50S ribo-
somal proteins, there has been a more recent surge in 
reports on mobile, transferable resistance mechanisms, 
such as the cfr gene [8], or the optrA gene [9], the latter 
being more often attributed to enterococci. Factors pos-
tulated to confer risk for linezolid resistance are disease 
severity, length of intensive care unit (ICU) stay, and 
exposure to linezolid [10–13]. According to one sys-
tematic review with meta-analysis from 2020, the global 
prevalence of linezolid resistance is reportedly still rather 
low [14]. Several outbreaks and clusters however, have 
indicated that especially linezolid-resistant S. epidermidis 
(LRSE) can manifest as an endemic pathogen in ICUs 
and that these are linked to a preceding linezolid overuse 
in most cases [10, 15–18].
Here, we report the spread of LRSE in an ICU in south-
west Germany, including an in-depth genetic characteri-
zation of isolates, and describe the effects of infection 
control and antimicrobial stewardship measures.
Methods
Design, study population, and setting
This report was designed as a before-after study to inves-
tigate the effects of infection control and antimicrobial 
stewardship interventions [19]. The reporting adhered to 
the ORION guidelines [20]. We compared the pre-inter-
vention period from May 2018 to April 2019 with the 
post-intervention period from May 2019 to April 2020.
A positive case was defined as having a LRSE in any 
clinical specimen, excluding screening specimens. Each 
patient was included only once, and only a single iso-
late was investigated per patient. Linezolid resistance 
was diagnosed when the confirmatory testing yielded a 
minimal inhibitory concentration (MIC) of > 4  mg/L, in 
accordance with the guidelines of the European Commit-
tee on Antimicrobial Susceptibility Testing (EUCAST). 
We performed a subgroup analysis on patients with LRSE 
detected in blood cultures. The intervention was per-
formed on a predominantly surgical intensive care unit 
with 26 beds at the Saarland University Medical Center, 
a large university hospital in southwest Germany, with a 
total of 1288 beds.
Interventions
Infection control practices were implemented in July 
2018, including isolation and cohorting of patients, as 
well as contact precaution comprising glove and gown 
use in the care of patients with LRSE. At the same time, 
a catheter-care bundle was initiated, comprising the 
development of a standard operating procedure, the use 
of chlorhexidine-impregnated dressings and specific luer 
access valve caps with 70% isopropyl alcohol for central 
venous catheters, and reinforcing a policy to discourage 
blood cultures from indwelling arterial catheters.
After a review of data on antibiotic use, we conceived 
an antibiotic stewardship intervention, initiated at the 
beginning of May 2019, aiming at the reduction of lin-
ezolid use and endorsing vancomycin. The intervention 
consisted of regular audits with feedback, educational 
meetings, and provision of pocket cards on the use of 
antibiotics with Gram-positive coverage (Additional 
file 1: Figure S1, available as Supplementary data). When 
indicated, vancomycin was recommended, while the use 
of linezolid, but also daptomycin were discouraged.
Microbiological diagnostics
All LRSE isolates were detected using standard micro-
biological procedures. In brief, bacteria were identi-
fied after growth on blood agar or other agar media by 
matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) using a Micro-
flex LT mass spectrometer (Bruker Daltonics; Bremen, 
Germany).
Antimicrobial susceptibility testing was performed 
employing VITEK II (BioMérieux; Marcy l’Étoile, France) 
and confirmatory testing with MIC Test Strip (Lio-
filchem; Roseto degli Abruzzi, Italy). For interpretation, 
the guidelines of the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST; versions 9.0 and 
10.0) were followed.
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Whole‑genome sequencing (WGS) and WGS‑based 
genotyping
Whole-genome sequencing (WGS) of available LRSE was 
performed using long-read Pacific Biosciences technol-
ogy (Pacific Biosciences Inc., Menlo Park, CA, USA). In 
brief, high molecular weight DNA was extracted using 
Monarch Genomic DNA Purification Kit (New England 
Biolabs, MA, USA) prior to library preparation using the 
SMRTbell Express Template Prep Kit 2.0 (Pacific Bio-
sciences Inc.). The DNA polymerase/template complex 
was prepared using the Sequel Binding Kit 2.1 (Pacific 
Biosciences Inc.) and sequenced on a Sequel II system 
(Pacific Biosciences Inc.). The resulting sequences were 
assembled using the microbial assembly pipeline inte-
grated in the SMRT Link version 8 software with default 
parameters (Pacific Biosciences Inc.). Gene sequences 
were extracted for subsequent core genome multilocus 
sequence typing (cgMLST)-based typing using an ad hoc 
cgMLST scheme consisting of 1,846 genes (Additional 
file  2: Table  S1, available as Supplementary data) and 
 SeqSphere+ software version 6 (Ridom GmbH, Münster, 
Germany) using default parameters as described else-
where [21]. For backwards compatibility with previous 
typing efforts, the MLST sequence types (STs) were also 
extracted with the help of the  SeqSphere+ software.
To determine the genetic basis of the linezolid resist-
ance, we analysed the genome sequences using the 
NCBI AMRFinderPlus [22] integrated in the  SeqSphere+ 
software.
Outcomes
Detection of LRSE in blood cultures and other clinical 
specimens was analysed on a monthly basis. In addi-
tion, we calculated medians per month to account for 
variability. We investigated the quarterly trends (i.e. for 
three consecutive months each) of LRSE rates, both, 
per S. epidermidis in all specimens (LRSE per S. epider-
midis), and per patient activity (per 10,000 patient-days) 
for both time periods. May to July 2018 was designated 
as quarter (Q) 1.1, August to October 2018 as Q1.2, 
November 2018 to January 2019 as Q1.3, and February 
2019 to April 2019 as Q1.4. Likewise, the quarters for 
the post-intervention period were designated as Q2.1, 
2.2, 2.3, and 2.4. Antibiotic consumption was assessed by 
calculating defined daily doses (DDD), according to the 
ATC/DDD index of the WHO Collaborating Centre for 
Drug Statistics Methodology, per 100 patient-days (PD) 
per month for intravenous vancomycin (DDD = 2  g), 
intravenous linezolid (DDD = 1.2  g), and intravenous 
daptomycin (DDD = 0.28  g). For the assessment of time 
trends, we calculated slope changes. To assess whether 
the propagated use of vancomycin was associated with 
target attainment, therapeutic drug monitoring including 
the number of vancomycin trough level orders and the 
respective trough levels were analysed.
We considered potential confounders such as length 
of stay, case mix, and in-house mortality. In addition, to 
minimize the risk that a change in ordering behaviour or 
contamination rates may have influenced the results, the 
number of ordered blood cultures, and the rate of blood 
cultures positive with S. epidermidis were investigated as 
well.
Vancomycin trough levels
Vancomycin trough levels were measured with an immu-
noassay utilizing a competitive assay format in which 
microparticles agglutinate (Cobas 8000 c702, Roche 
Diagnostics; Mannheim, Germany).
Ethics
Due to the nature of nosocomial infections, all diagnostic 
and interventional aspects of this work were performed 
in accordance with the German Protection against Infec-
tion Act (Infektionsschutzgesetz). Hence, an ethics 
approval was not necessary. All patient-related data were 
anonymized.
Statistical methods
We performed statistical analyses by using GraphPad 
Prism (GraphPad Software Inc.; California, USA). We 
compared the pre-intervention period to the post-inter-
vention period using Mann–Whitney U test and t test for 
continuous variables; chi-square and Fisher’s exact test 
for categorical data; and nonlinear regression analysis 
for discrete changes of antibiotic utilization. The level for 
statistical significance was set at 0.05.
Results
Microbiology
Between May 1, 2018 and April 30, 2019, 31 patients 
were identified with LRSE in any clinical speci-
men (median 2 per month, interquartile range, IQR, 
1–4). Of these, 17 had LRSE detected in blood cul-
ture (median 1 per month, IQR 0–2). In comparison, 
in the post-intervention period from May 1st 2019 to 
April 30th 2020, a total of 6 patients had a detection 
of LRSE in any specimen (median 0 per month, IQR 
0–1) (p = 0.0065), with 4 being positive in blood cul-
ture (median 0 per month, IQR 0–0.8) (p = 0.1057) 
(Table 1) (Fig. 1). Analysis of quarterly trends or LRSE 
per S. epidermidis rates yielded 11/53 (20.8%), 4/53 
(7.5%), 10/68 (14.7%), and 6/70 (8.6%) cases for Q1.1, 
Q1.2, Q1.3, and Q1.4, showing a decrease in the post-
intervention period, with 1/66 (1.5%), 3/53 (5.7%), 2/53 
(3.8%), and 0/60 (0%) cases respectively during Q2.1, 
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Q2.2, Q2.3, and Q2.4. Likewise, LRSE rates per patient 
activity yielded a decrease, from 57.4/10,000 PD, 
22.2/10,000 PD, 57.0/10,000 PD, and 31.6/10,000 PD 
during the pre-intervention quarters, to 5.2/10,000 PD, 
16.1/10,000 PD, 10.6/10,000 PD, and 0/10,000 PD in the 
post-intervention period quarters, respectively.
Table 2 shows the annual trend before the interven-
tion, as compared to all other departments of the same 
hospital.
Table 1 Comparative main study outcomes during the pre- and post-intervention study periods in an investigation of a spread of 
linezolid-resistant Staphylococcus epidermidis on an intensive care unit in southwest Germany, 2018–2020
p-values of significant differences are shown in bold
LRSE linezolid-resistant Staphylococcus epidermidis, IQR interquartile range, DDD defined daily doses, PD patient-days, no. number
Pre‑intervention Post‑intervention p‑value
Microbiological outcomes
LRSE in any specimen, median per month (IQR) 2 (1–4) 0 (0–1) 0.0065
LRSE in blood culture, median per month (IQR) 1 (0–2) 0 (0–0.8) 0.1057
Antibiotic consumption outcomes
Median linezolid consumption, in DDD/100 PD per month (IQR) 7.5 (4.6–10.8) 2.5 (0.9–4.8) 0.0022
Median daptomycin consumption, in DDD/100 PD per month (IQR) 12.3 (6.2–22.4) 5.7 (1.4–10.7) 0.0205
Median vancomycin consumption, in DDD/100 PD per month (IQR) 0.2 (0–0.4) 4.7 (2–6)  < 0.0001
Combined median antibiotic consumption for all three substances, in 
DDD/100 PD per month (IQR)
21.9 (13.8–29.6) 14.8 (8.0–17.6) 0.0233
Therapeutic drug monitoring
Number of vancomycin trough level measurements 16 221
Median trough level, in µg/mL (IQR) 10.2 (8.1–13.7) 12.6 (10.2–16.2)  < 0.0001
Target attainment (i.e. 10- < 20 µg/mL) (%) 6/16 (37.5%) 144/221 (65.2%) 0.0331
Potential confounders
Total number of blood cultures taken 1650 1668
Blood cultures positive for Staphylococcus epidermidis, n (%) 175 (10.6%) 156 (9.4%) 0.2466
Length of stay, days (mean) 4.9 5.6 0.23
Case-mix-index (mean) 4.9 5.3 0.11















































































































Daptomycin Linezolid Vancomycin LRSE BC pos. LRSE
Fig. 1 Antibiotic consumption and the incidence of LRSE over time for each month; antibiotic consumptions per substance are shown in 
columns, the number of LRSE total (yellow) and in blood cultures (blue) as curves. DDD/100 PD: defined daily dose per 100 patient-days; LRSE 
linezolid-resistant Staphylococcus epidermidis, BC blood culture, pos. positive
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Whole‑genome sequencing
Overall, 31 isolates were subjected to WGS. Whereas all 
31 isolates were MLST ST2, WGS revealed that all except 
one isolate (patient 31) were closely related with ≤ 4 
allelic differences in a pairwise comparison to the neigh-
bouring isolate indicating a clonal spread of LRSE. The 
isolate of Patient 31 is only distantly related to the other 
30 LRSE with ≥ 53 alleles differing to all other LRSE iso-
lates of the cluster (Fig. 2). We then screened the genome 
sequences for the presence of known genes that are 
associated with linezolid resistance phenotypes, how-
ever, we were not able to find any known gene (such as 
cfr) associated with linezolid resistance using the NCBI 
AMRFinderPlus.
Antibiotic consumption
Median linezolid consumption during the pre-interven-
tion period was 7.5 DDD/100 patient days (IQR 4.6–
10.8), decreasing to 2.5 DDD/100 PD (IQR 0.9–4.8) in the 
post-intervention period (p = 0.0022) (Table 1) (Fig. 1).
We observed gradual changes within the pre-interven-
tion period, with a slope of -0.336 (95% confidence inter-
val -1.002 to 0.3296). This downward slope was stronger 
Table 2 Percentage of linezolid-resistant strains among all Staphylococcus epidermidis in all materials over the time, counted once per 
patient, for the index ICU in comparison with the rest of the hospital, between 2014 and 2020




2020 (up until 
April 30th) (%)
Index ICU 0 2 1 7 10 8 4 0
Rest of hospital 0 0 0 1 2 3 2 2
Fig. 2 Minimum spanning tree of 31 LRSE isolates. Each circle represents the genotype based on a unique allelic profile of up to 1846 cgMLST 
genes (ignoring missing values in pairwise comparisons) and the number on connecting lines display the number of differing alleles. The circles are 
named with the isolates and their size is proportional to the number of isolates with the same genotype
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in the post-intervention period with -0.3692 (95%CI 
-0.93 to 0.1916) (Fig. 3).
Similarly, daptomycin usage decreased from 12.3 
DDD/100 PD (IQR 6.2–22.4) in the pre-intervention 
period to 5.7 DDD/100 PD (IQR 1.4–10.7) in the post-
intervention period (p = 0.0205) (Table 1).
Utilization of vancomycin was promoted, which led 
to an increase of a median of 0.2 DDD/100 PD (IQR 
0–0.4) to 4.7 DDD/100 PD (2–6) (p < 0.0001) (Table 1). 
Concurrently, the slope increased from 0.03 (95% CI 
-0.07 – 0.14) in the pre-intervention period to 0.12 
(95% CI -0.33 – 0.56) in the post-intervention period.
Detailed analyses of the gradual changes are shown in 
Fig.  3. Combined utilization of linezolid, daptomycin, 
and vancomycin decreased significantly (Table 1).
Fig. 3 Antibiotic utilization in defined daily dose per 100 patient-days (DDD/100 PD), for each month of both study periods, for linezolid, 
daptomycin, and vancomycin (from top to bottom)
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Vancomycin target attainment
We monitored vancomycin trough level orders and tar-
get attainment. Vancomycin trough levels increased from 
16 to 221 measurements in the post-intervention period. 
Median trough levels were 10.2  µg/mL (IQR 8.1–13.7) 
in the pre-intervention period compared to 12.6  µg/
mL (IQR 10.2–16.2) in the post-intervention period 
(p < 0.0001). Target attainment, defined as a trough level 
between 10 and < 20 µg/mL, was significantly more often 
met in the post-intervention period with 144/221 (65.2%) 
than in the pre-intervention period with 6/16 (37.5%) 
(p = 0.0331) (Table 1).
Length of stay, case‑mix‑indices and mortality
Between the two time periods, we observed no statisti-
cally significant difference in mean length of stay, case-
mix-indices, mortality, number of blood cultures taken, 
and the rate of blood cultures positive for all S. epider-
midis (Table  1). However, the shift in antibiotic utili-
zation led to monetary savings for antibiotics in the 
magnitude of 16,283.05 € for the year 2019 (Additional 
file  3: Table  S2, available as Supplementary data), disre-
garding other costs, such as those related to, for example, 
therapeutic drug monitoring.
Discussion
Here, we report a spread of LRSE in an ICU linked to and 
perpetuated by an unrestricted use of linezolid, which 
we successfully controlled by combined infection control 
and antimicrobial stewardship measures with sustained 
effects after one year. Of note, these interventions were 
not associated with a worse clinical outcome as mortality 
rates remained unchanged.
Our WGS findings suggest that a single clone was 
predominant at the ward with 30 of 31 isolates sharing 
nearly identical genotypes, which in concurrence with 
the high linezolid use led to an extensive spread, but was 
at the same time reversible by significantly reducing lin-
ezolid utilization rates.
Interestingly, although 30 of 31 isolates clearly 
belonged to the same single clone, we detected 20 dif-
ferent genotypes with a maximum difference of 10 
alleles within the cluster (Fig.  2). This, however, could 
be explained by the fact that the outbreak period was 
spanning a longer time period, which very likely ena-
bled LRSE to further diversify. Such micro-evolution-
ary events frequently take place in prolonged outbreaks 
such as shown for Listeria monocytogenes [23] or 
Staphylococcus aureus [24]. Several nosocomial out-
breaks of LRSE have been reported in the past years, 
most of which focused on the molecular epidemiology 
and genetic characterization of the microorganisms 
[10, 15–18]. Descriptions of antimicrobial stewardship 
interventions are scarce [12] or lack details that would 
facilitate reproducibility [25–27].
The causal link between linezolid overuse and emer-
gence of linezolid resistance had been demonstrated pre-
viously [25, 26]. Mulanovich and colleagues postulated 
that exceeding a certain threshold of selection pressure, 
i.e. 13 DDD/100 PD would be necessary for the occur-
rence of an outbreak [28]. Of note, we observed that the 
continuity of an outbreak may depend on even lower 
DDD thresholds, notwithstanding appropriate infection 
control measures.
While antibiotic cycling, i.e. the projected shift in anti-
biotics used in a certain unit over time, has been con-
troversially debated with high-quality evidence showing 
no benefit [29], a change in antibiotic treatment strategy 
has been demonstrated to be effective in outbreaks with 
other organisms as well [30]. Here, vancomycin was pro-
moted as first-line antibiotic for patients with presumed 
infection due to Gram-positive, beta-lactam-resistant 
bacteria.
The strengths of our study are the ambidirectional 
design, allowing for a prospective evaluation of the anti-
microbial stewardship intervention; the length of the 
study period to account for secular time trends [31]; 
and the availability of isolates for WGS analysis to prove 
genetic linkage.
Some limitations deserve mentioning. We did not per-
form routine colonization surveillance of LRSE, which 
would have helped to estimate the effect of the interven-
tions on the colonization prevalence. In the absence of an 
established and common screening method for linezolid-
resistant bacteria, it is conceivable that the actual number 
of patients with LRSE colonization was higher than our 
numbers reflected. Furthermore, our report lacks investi-
gations of environmental surfaces and health-care work-
ers (HCW), albeit plausible that the latter could have 
been a vector in most cases. Still, it appears reasonable 
to postulate that, even in the absence of a pre-coloniza-
tion with LRSE, linezolid may have suppressed resident 
microbiota and thereby enabled transmission and infec-
tion by LRSE, as also stated by Weßels and colleagues 
[25]. Moreover, it can be argued that attributing an 
outcome to one specific cause is hampered by the mul-
tifaceted nature of a combined intervention, compris-
ing infection control measures such as the catheter-care 
bundle, and antimicrobial stewardship measures. Finally, 
we assessed DDDs, but not individual lengths or days of 
therapy, thereby potentially introducing a minor degree 
of imprecision. Nevertheless, linezolid consumption 
quantified by DDD for the overall hospital remained sta-
ble from mid-2018 through mid-2020 (data not shown), 
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thus refuting a secular trend which could have been 
underlying the observed changes within the index ward.
The success of our intervention may have been influ-
enced by the nature and depth of the antimicrobial 
stewardship intervention, i.e. educational efforts put in 
the endorsement of vancomycin, which had been sel-
dom used previously on the index ICU. This was nota-
bly underscored by the vancomycin utilization rate, the 
increased use of therapeutic drug monitoring and the 
substantial improvement in target attainment during the 
post-intervention period.
Conclusions
In conclusion, our report demonstrates a successful LRSE 
control composed of infection control measures com-
bined with an antimicrobial stewardship intervention. 
Future studies should evaluate the benefit of colonization 
surveillance, and address the question whether HCW 
screening and decolonization strategies may be of addi-
tional help in controlling outbreaks or clusters of LRSE.
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